Gabriel Morris
Director of Finance/CFO chez IMMIX BIOPHARMA, INC.
Fortune : 991 054 $ au 31/03/2024
Profil
Gabriel A.
Morris is currently the Chief Financial Officer & Director at Immix Biopharma, Inc., Managing Partner at Alwaysraise LLC, and President at Nexcella, Inc. He previously worked as the Chief Operating Officer at Campbell & Co. LP and as the Chief Financial Officer at ZAP Surgical Systems, Inc. Mr. Morris completed his undergraduate degree at The Trustees of Columbia University in The City of New York.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMMIX BIOPHARMA, INC.
1,26% | 14/08/2023 | 322 819 ( 1,26% ) | 991 054 $ | 31/03/2024 |
Postes actifs de Gabriel Morris
| Sociétés | Poste | Début |
|---|---|---|
| IMMIX BIOPHARMA, INC. | Director of Finance/CFO | 01/03/2021 |
| Alwaysraise LLC | Corporate Officer/Principal | 01/01/2020 |
Nexcella, Inc.
 Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | President | - |
Anciens postes connus de Gabriel Morris
| Sociétés | Poste | Fin |
|---|---|---|
Campbell & Co. LP
 Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Chief Operating Officer | 03/01/2021 |
ZAP Surgical Systems, Inc.
 ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Director of Finance/CFO | 01/01/2020 |
Formation de Gabriel Morris
| The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| IMMIX BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Campbell & Co. LP
Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Finance |
ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Technology Services |
| Alwaysraise LLC | |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
